Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival
Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Stéphane Culine(Radboud University Nijmegen), I. Latorzeff(Clinique Pasteur), Philippe Beuzeboc(Hôpital Foch), Frank Priou, Emmanuel Sevin, R. Delva, F. Rolland(Institut de Cancérologie de l'Ouest), E. Banu, R.T. Elaidi, Armelle Caty
Cited by 3
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603